Lithium-based regenerative therapy for curing Glaucoma: Repurposing the antipsychotic drug Lithium into an anti-glaucoma agent: Lithium, used in the treatment of bipolar disorder & depression, increases the expression of genes that promote regeneration,  promotes reprogramming of aged eye cells, increases telomerase expression, increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against and reverses glaucoma,  via up regulation of its target gene, 1/December/2019, 11.56 pm

Treating advanced cancers resistant to Paclitaxel/Topotecan/Temozolomide: Probiotic-based Chemotherapy (PCT) targeting cancer stem cells and immune-inhibitory receptors in advanced ovarian cancer and in other advanced metastatic cancers resistant to Paclitaxel/Topotecan/Temozolomide: A pharmaceutical mixture encompassing Veliparib (ABT-888) and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as BTG2, BIRC5, p53, and TA-p73/p63, INK4a and others, decreases PP2A expression, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance mediated by Paclitaxel/Topotecan/Temozolomide, and stalls advanced ovarian cancers  progression, and prolongs survival, via up-regulation of its target gene, 29/November/2019, 4.20 pm
November 29, 2019
Vitamin-E based therapy for pain management: Mechanistic insights into how VitmainE isoform γ-tocotrienol (γT3) functions as an analgesic agent: γ-tocotrienol (γT3) increases the expression of PD-L1, decreases the expression of Cox-2, TRPV1, and CGPR, attenuates acute and chronic pain, and suppresses mechanical and thermal hypersensitivity and inhibits nociceptive neuron excitability, via up-regulation of its target gene, 3/November/2019, 9.29 am
December 3, 2019
Show all

Introduction: What they say

A study from the The Jackson Laboratory, Bar Harbor, ME 04609, USA; Department of Ophthalmology, Tufts University of Medicine, Boston, MA 02111, USA; The Howard Hughes Medical Institute, Bar Harbor, ME 04609, USA shows that Vitamin B3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice.” This research paper was published, in the 9 February 2017 issue of the journal “Science” [One of the best research journals in “General Science” with an I.F of 41.063], by     Prof. Simon W. M. John and Pete A. Williams and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Lithium-based regenerative therapy for curing Glaucoma: Repurposing the antipsychotic drug Lithium into an anti-glaucoma agent: Lithium, used in the treatment of bipolar disorder & depression, increases the expression of genes that promote regeneration,  promotes reprogramming of aged eye cells, increases telomerase expression, increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against and reverses glaucoma,  via up-regulation of its target gene


From the significance of the study to public health relevance:

Given that: (1) Glaucoma is a neurodegenerative disease; (2) more than 80 million people worldwide are affected by Glaucoma; (2) Glaucoma is the second leading cause of blindness; (3) Glucosma has no cure; (4) vision lost due to glaucoma is irreversible; (5) the global economic cost spent for Glaucoma treatment is enormous, there is an urgent need to find: (i) a way to induce regeneration of ganglion cells that were lost in Glaucoma; (ii) a cheaper alternative to the existing expensive anti-glaucoma drugs; (iii) a side-effect-free natural product-based drug; and (v) a way to cure, not just treat, Glaucoma permanently.


What is known?

Prof.Simon’s research team has recently shown that:(1) glaucoma-prone mice suffer from mitochondrial abnormalities, resulting in neuronal dysfunction; (2) NAD+ levels decrease with age; (3) administration of Niacin/Vitamin-B3 protects against glaucoma; (4) expression of Nmnat1, a key NAD+-producing enzyme, protects against glaucoma, suggesting that increasing the expression of Nmnat1 in glaucoma patients may alleviate glaucoma.


From research findings to Therapeutic opportunity:

This study suggests, for the first time, that Lithium, by increasing the expression of their target genes, it could increase the expression of Nmnat1. Thereby, it could: (1) increase NAD+ levels; (2) increase telomerase expression; (3) increase the expression of genes that promote regeneration; (4) promote reprogramming of aged eye cells; (5) decrease Intraocular pressure; (6) improve pressure-induced damage; (7) increase insulin sensitivity; and (8) alleviate/reverse glaucoma (Fig.1). Thus, Lithium or its derivatives either alone or in combination with other drugs, may be used to cure or reverse Glaucoma.

Figure 1. Mechanistic insights into how Lithium (chloride/carbonate) attenuates or cures glaucoma. Lithium, by increasing the expression of its target genes,  increases the expression of genes that promote regeneration and telomerase, enhances NAD+ levels, and attenuates/reverses/cures glaucoma.

Figure 2. Antipsychotic agent Lithium functions as an anti-glaucoma agent by increasing NAD+ levels

Figure 3. While it had been shown earlier that Vitamin-B3 prevents glaucoma in aged mice, its mechanism of action remains largely unclear. This study suggests that antipsychotic drug Lithium could promote reprogramming of aged eye cells and reverse glaucoma by upregulating the expression of NMNAT1, and telomerase, and increase the levels of NAD+, and genes that promote regeneration.


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does Lithium increase the levels of NAD+?

Amount: $1, 500#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org


References:

Web: http://genomediscovery.org or http://newbioideas.com

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Citation: Boominathan, L., Lithium-based regenerative therapy for curing Glaucoma: Repurposing the antipsychotic drug Lithium into an anti-glaucoma agent: Lithium, used in the treatment of bipolar disorder & depression, increases the expression of genes that promote regeneration,  promotes reprogramming of aged eye cells, increases telomerase expression, increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against and reverses glaucoma,  via upregulation of its target gene, 1/December/2019, 11.56 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Comments are closed.